Identification of a Functional Epitope in Plasminogen Activator Inhibitor-1, not Localized in the Reactive Center Loop

Summary

Plasminogen activator inhibitor-1 (PAI-1) is unique among the ser-pins because of its conformational flexibility. Previously, we have characterized monoclonal antibodies that neutralize PAI-1 activity by switching the active, inhibitory pathway into the non-inhibitory substrate pathway (10). Here, we report the identification of the epitopes for two of these antibodies, i.e. MA-55F4C12 and MA-33H1 and apply this information to explain their functional effects.

Using a random PAI-1 epitope library (11), phages displaying specific PAI-1 fragments were isolated after selective screening for binding onto the respective antibodies. Competition experiments with PAI-1 demonstrated that selected phages react with the antigen-binding site of the antibodies. Comparison of the sequences of the different overlapping inserts, encoding the PAI-1 epitope, with the PAI-1 cDNA sequence revealed that both epitopes, even though not identical, are located between amino acids Glu128 and Ala156 in the PAI-1 molecule. Analysis within the three-dimensional structure of PAI-1 showed that these residues completely cover helix F, which is localized close to the major β-sheet A. This localization provides a rational basis for explaining the mechanism of PAI-1 inactivation by both antibodies: upon binding of these antibodies to PAI-1, a stabilizing effect is induced on helix F resulting in a decrease of the kinetics of insertion of the reactive site loop into β-sheet A during interaction with the target proteinase. This forms the molecular basis for the observed functional effects of these antibodies and fully explains why PAI-1, in the presence of these antibodies, has lost its inhibitory properties but remains succeptible to cleavage by its target proteinases. The identification and localization of these functionally important epitopes opens new perspectives for the development of pharmacological agents with PAI-1 modulating properties.

• References

• 1 Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, van Zonneveld A-J, Van Mourik JA. Endothelial plasminogen activator inhibitor (PAI): a new member of the serpin gene family. EMBO J 1986; 5: 2539-44.
• 2 Ny T, Sawdey M, Lawrence D, Milan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776-80.
• 3 Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, Danø K, Lebo RV, Gelehrter TD. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 1986; 78: 1673-80.
• 4 Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Danø K. Plasminogen activator inhibitor type 1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 1986; 209: 213-8.
• 5 Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-11587.
• 6 Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270-3.
• 7 Declerck PJ, De Mol M, Vaughan DE, Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a non-inhibitory substrate for tissue-type plasminogen activator. J Biol Chem 1992; 267: 11693-6.
• 8 Urano T, Strandberg L, Johansson LB, Ny T. A substrate-like form of plasminogen activator inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 1992; 209: 985-92.
• 9 Munch M, Heegaard CW, Andreasen PA. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim Biophys Acta 1993; 1202: 29-37.
• 10 Debrock S, Declerck PJ. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochim Biophys Acta 1997; 1337: 257-66.
• 11 van Zonneveld A-J, van den Berg BMM, van Meijer M, Pannekoek H. Identification of functional interaction sites on proteins using bacteriophage-displayed random epitope libraries. Gene 1995; 167: 49-52.
• 12 Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-7.
• 13 Gils A, Knockaert I, Declerck PJ. Substrate behaviour of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Biochemistry 1996; 35: 7474-81.
• 14 Debrock S, Declerck PJ. Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor 1 after cleavage of the reactive center loop or after complex formation with various serine proteinases. FEBS Lett 1995; 376: 243-6.
• 15 Ey PL, Prowse SJ, Jenkins CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immuno-chemistry 1978; 15: 429-36.
• 16 Barbas III CF, Kang AS, Lerner RA, Benkovic SJ. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci USA 1991; 88: 7978-82.
• 17 Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A laboratory manual. 2nd Ed New York: Cold Spring Harbor, NY; 1989
• 18 Declerck PJ, Alessi M-C, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor-1 in biological fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-5.
• 19 Declerck PJ, Verstreken M, Collen D. Measurement of different forms of plasminogen activator inhibitor 1 (PAI-1) using various monoclonal antibody-based enzyme-linked immunosorbent assays. Fibrinolysis 1990; 4 (Suppl. 02) 132-3.
• 20 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Thromb Haemost 1985; 54: 684-7.
• 21 Gettins P, Patson PA, Shapira M. The role of conformational change in serpin structure and function. Bioessays 1993; 15: 461-4.
• 22 Hood DB, Huntington JA, Getting PG. Alpha 1-proteinase inhibitor variant T345R. Influence of P14 residue on substrate and inhibitory pathways. Biochemistry 1994; 33: 8538-47.
• 23 Lawrence DA, Olson ST, Palaniappan S, Ginsburg D. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition. J Biol Chem 1994; 269: 27657-62.
• 24 Nielsen LS, Andreasen PA, Grondahl-Hansen J, Huang J-Y, Kristensen P, Danø K. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells: inhibitor neutralizing and one-step affinity purification. Thromb Haemost 1986; 55: 206-12.
• 25 Keijer J, Linders M, van Zonneveld A-J, Ehrlich HJ, de Boer J-P, Pannekoek H. The interaction of plasminogen activator inhibitor-1 (PAI-1) with plasminogen activators (t-PA, u-PA) and fibrin: localization of interaction sites and physiological relevance. Blood 1991; 78: 401-9.
• 26 MacGregor IR, Tonner AM, Micklem LR, James K, Booth NA. Murine monoclonal antibodies against active site epitopes on human endothelial plasminogen activator inhibitor (PAI-1). Fibrinolysis 1990; 4: 27-34.
• 27 Perrie AM, MacGregor IR, Booth NA. Definition of epitopes within plasminogen activator inhibitor type-1 (PAI-1) using multiple peptide synthesis. Fibrinolysis 1993; 7: 257-63.
• 28 Van Meijer M, Klein Gebbink R, Preissner KT, Pannekoek H. Determination of the vitronectin binding site on plasminogen activator inhibitor-1 (PAI-1). FEBS Lett 1994; 352: 342-6.
• 29 Lawrence DA, Berkenpas MB, Palaniappan S, Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 1994; 269: 15223-8.
• 30 Padmanabhan J, Sane DC. Localization of a vitronectin binding region on plasminogen activator inhibitor-1. Thromb Haemost 1995; 73: 829-34.
• 31 Declerck PJ, De Mol M, Alessi MC, Baudner S, Pâques EP, Preissner KT, Müller-Berghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor-1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263: 15454-61.
• 32 Kraulis PJ. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 1991; 24: 946-50.
• 33 Aertgeerts K, De Bondt HL, De Ranter CJ, Declerck PJ. A model of the reactive form of plasminogen activator inhibitor-1. J Struct Biol 1994; 113: 239-45.